Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
NCT ID: NCT05534087
Last Updated: 2024-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
236 participants
INTERVENTIONAL
2022-12-15
2030-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Using circulating tumor DNA (ctDNA)-based minimal residual cancer (MRD) detection technology, patients whose MRD is not eradicated after adjuvant chemotherapy could be identified. Early introduction of intensified chemotherapy for this group of patients could prolong survival time and increase cure rates.
This study is part of the Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (CLADIA Colon Cancer). Part 1 of the platform study (Prospective Observational Study of ctDNA Monitoring During Adjuvant) is a large-scale, prospective observational study that follows ctDNA up to three years after resection in about 1,200 patients with stage 2-3 colon cancer.
This study (Part 2) aims to study the efficacy of early intensified chemotherapy (3 months of modified FOLFIRINOX ) compared to standard treatment (FOLFOX/CAPOX for an additional three months to complete six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX/CAPOX chemotherapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mFOLFIRINOX intensified chemotherapy
6 cycles of mFOLFIRINOX
\- Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks
mFOLFIRINOX-FOLFIRI intensified chemotherapy
(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks
* Oxaliplatin 85mg/m2 IV infusion over 120 min D1
* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)
* Irinotecan 150mg/m2 IV infusion over 60-90 min D1
* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2
FOLFOX or CAPOX adjuvant chemotherapy
FOLFOX 6 cycles or CAPOX 4 cycles
* FOLFOX regimen: 6 cycles every 2 weeks or
* CAPOX regimen: 4 cycles every 3 weeks
FOLFOX or CAPOX adjuvant chemotherapy
1. FOLFOX regimen: 6 cycles every 2 weeks
* Oxaliplatin 85mg/m2 IV infusion over 120 min D1
* Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)
* 5-fluorouracil 400mg/m2 IV bolus D1
* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or
2. CAPOX regimen: 4 cycles every 3 weeks
* Oxaliplatin 130mg/m2 IV infusion over 120 min D1
* Capecitabine 1,000mg/m2 PO bid D1-14
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mFOLFIRINOX-FOLFIRI intensified chemotherapy
(1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks
* Oxaliplatin 85mg/m2 IV infusion over 120 min D1
* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)
* Irinotecan 150mg/m2 IV infusion over 60-90 min D1
* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2
FOLFOX or CAPOX adjuvant chemotherapy
1. FOLFOX regimen: 6 cycles every 2 weeks
* Oxaliplatin 85mg/m2 IV infusion over 120 min D1
* Leucovorin 400mg/m2 IV infusion over 120 min (concurrently with oxaliplatin)
* 5-fluorouracil 400mg/m2 IV bolus D1
* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2 or
2. CAPOX regimen: 4 cycles every 3 weeks
* Oxaliplatin 130mg/m2 IV infusion over 120 min D1
* Capecitabine 1,000mg/m2 PO bid D1-14
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age range of 19 to 75 years
3. Adenocarcinoma of colon confirmed by histology
4. Patients with stage II-III colon cancer as defined by the American Joint Committee on Cancer's eighth edition (Stage II cancer is limited to patients who are at a high risk, with more than one risk factor for recurrence.)
5. Patients who have completed the sixth cycle of FOLFOX or the fourth cycle of CAPOX adjuvant chemotherapy for colon cancer following radical resection (R0 resection)
6. A ctDNA test performed 3 to 6 weeks after surgery reveals a positive MRD
7. ECOG performance scale of 0-1 (only 1 is allowed for 70-75 years old)
8. Adequate bone marrow function \[ANC ≥1,300/LL, platelets ≥75,000/LL, hemoglobin ≥8.0g/dL (may be eligible in study if intermittent transfusion is required)\]
9. Appropriate liver function (total bilirubin ≤1.5xULN, AST and ALT ≤3xULN)
10. Appropriate renal function (serum creatine ≤1.5xULN, renal clearance rate ≥50 ml/min)
11. Patients who are deemed to understand the study protocol and are willing to participate in the trial until it is completed
Exclusion Criteria
2. Pregnant women who had a positive pregnancy test at the time of the baseline examination (postmenopausal women must be amenable for at least 12 months to be considered non-fertility)
3. Sexually active men and women of reproductive age who are unwilling to use contraception throughout the study treatment and for a period of 6 months (female) or 3 months (male) following the discontinuation of study treatment
4. Clinically significant heart condition \[unstable angina requiring medication, symptomatic coronary artery disease, congestive heart failure, or significant heart arrhythmia above NYHA II, or acute coronary syndrome, including myocardial infarction within the last 6 months\]
5. Active viral infections such as HIV (However, HBV carriers may enroll if their HBV DNA titer is less than 20,000 IU/ml, and antiviral drugs for hepatitis B may be administered prophylactically at the investigator's discretion)
6. Significant uncontrolled infections or other uncontrolled comorbidities
7. Symptomatic inflammatory bowel disease
8. Allogeneic transplantation history necessitating immunosuppressive therapy
9. A history of other malignancies identified within the last three years, except for completed removed basal cell carcinoma of the skin, completely removed cervical epithelial carcinoma, and thyroid cancer that has been treated, including surgery
10. Recurrent or residual disease identified clinically or radiographically
11. Previous history of irinotecan treatment
12. Polyposis including familial adenomatous polyps
13. Two or more colon or rectal cancers with a pathologic stage greater than II that were detected concurrently or within the last three years
14. When the investigator determines that the subjects' safety may be jeopardized during the study because of other serious or unstable pre-existing medical or mental conditions
15. Prior clinical trial participation and usage of investigational drugs or devices following radical resection of colon cancer
16. Patients with peripheral neuropathy who have a CTCAE v5 grade 3 or higher functional disability (corresponds to "severe symptoms, limiting self-care activity of daily living" according to CTCAE v5 criteria)
17. Previous anaphylactic reaction or severe and unexpected reactions to fluoropyrimidines or platinum
18. Gilbert's syndrome, dehydro-pyridine dehydrogenase (DPD) deficiency, or homozygous UGT1A1\*28 alleles
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sae-Won Han
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sae-Won Han, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital South Korea
Youngjun Cha, MD
Role: STUDY_DIRECTOR
Natioal Cancer Center South Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Center
Goyang, , South Korea
Jin Won Kim
Seongnam, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yongjun Cha
Role: primary
Jin Won Kim
Role: primary
Sae-Won Han
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2205-029-1322
Identifier Type: -
Identifier Source: org_study_id